Related Experiment Video

Updated: Apr 29, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

7.6K

The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease

Victoria Pozzi-Ruiz1, Aida Giner de Gracia1, Liliane Glauser2

  • 1Laboratory of Functional Epi-Genomics of Aging and Alzheimer's disease, Instituto de Neurociencias, Universidad Miguel Hernández-Consejo Superior de Investigaciones Científicas (UMH-CSIC), Alicante, Spain.

Cell Death & Disease
|April 27, 2026
PubMed

Insights

Peptidase M20 Domain Containing 1 (PM20D1) derived N-oleoyl-Leucine (OLE) enhances microglia

Area of Science:

  • Neuroscience
  • Immunology
  • Biochemistry

Background:

  • Microglia play a crucial role in Alzheimer's disease (AD) pathogenesis.
  • Modulating microglial activity presents a therapeutic strategy for AD.
  • Peptidase M20 Domain Containing 1 (PM20D1) is a recently identified AD-associated gene.

Purpose of the Study:

  • To investigate the mechanism by which PM20D1 influences microglia in AD.
  • To evaluate the therapeutic potential of PM20D1-derived N-oleoyl-Leucine (OLE) in AD models.
  • To explore OLE's effects on amyloid-beta (Aβ) pathology and neuroprotection.

Main Methods:

  • Utilized two animal models of AD.
  • Assessed OLE's impact on microglia-amyloid plaque interaction, plaque burden, and neurotoxicity.
  • Examined Aβ clearance and neuronal viability in microglia cultures and stressed neurons.
  • Analyzed human AD brain samples for PM20D1 and OLE-mediated effects.

Main Results:

  • OLE treatment reduced amyloid plaque size, number, and toxicity in AD models.
  • OLE promoted microglia association with amyloid plaques, enhancing Aβ clearance.
  • OLE improved neuronal viability under AD-related stress conditions.
  • Evidence of PM20D1 and OLE-mediated effects was observed in human AD brains.

Conclusions:

  • PM20D1-derived OLE demonstrates significant therapeutic potential for Alzheimer's disease.
  • OLE acts by instructing microglia to target amyloid pathology and provide neuroprotection.
  • OLE represents a promising microglia-modifying agent for AD treatment.

More Related Videos

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

15.6K
Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions08:47

Author Spotlight: In Vitro Co-Culture Model for Studying Microglia-Neuronal Interactions in Disease Conditions

Published on: July 26, 2024

3.3K

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
32
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
22
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
20
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K